Fig. 3From: Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational studyAsthma-related HCRU for patients in the provincial drug coverage subset pre- versus post-mepolizumabED, emergency department; GP, general practitioner; HCRU, healthcare resource utilization; OCS, oral corticosteroid; SABA, short-acting β-agonistBack to article page